Date | Price Target | Rating | Analyst |
---|---|---|---|
7/23/2024 | $22.00 | Overweight | Piper Sandler |
4/3/2024 | $37.00 | Buy | Craig Hallum |
7/13/2023 | $35.00 | Outperform | Northland Capital |
Piper Sandler initiated coverage of Indivior with a rating of Overweight and set a new price target of $22.00
Craig Hallum initiated coverage of Indivior with a rating of Buy and set a new price target of $37.00
Northland Capital initiated coverage of Indivior with a rating of Outperform and set a new price target of $35.00
SC 13G - INDIVIOR PLC (0001625297) (Subject)
SC 13G/A - INDIVIOR PLC (0001625297) (Subject)
SC 13D/A - INDIVIOR PLC (0001625297) (Subject)
SC 13G/A - INDIVIOR PLC (0001625297) (Subject)
SC 13G - INDIVIOR PLC (0001625297) (Subject)
SC 13D/A - INDIVIOR PLC (0001625297) (Subject)
Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company
FY 2024 Guidance On July 9th, the Group updated its financial guidance for FY 2024 to reflect continued near-term adverse market dynamics impacting SUBLOCADE NR growth as well as the initial commercial adoption of OPVEE and the cessation of PERSERIS sales and marketing. The guidance set out is unchanged from the July 9th guidance. At the midpoint, the Group expects solid adjusted operating profit growth of 12% and adjusted operating margin expansion of approximately 100 bas
Repurchases Under Current Program now Expected to be Completed by End of July RICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) ("Indivior" or the "Company"), a leading addiction treatment company, today announced that its Board of Directors has approved a new share repurchase program under which the Company will commence repurchasing Indivior's ordinary shares of $0.50 each (the "Ordinary Shares") for up to a maximum consideration of $100 million (the "New Program"). The New Program will be carried out on an accelerated basis and is expected to be completed over the next six months, subject to compliance with applicable trading restrictions
Indivior (NASDAQ:INDV) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.14 by 214.29 percent. This is a 12.82 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million by 1.00 percent. This is a 8.33 percent increase over sales of $276.00 million the same period last year.
Piper Sandler analyst David Amsellem initiates coverage on Indivior (NASDAQ:INDV) with a Overweight rating and announces Price Target of $22.
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 40 points on Tuesday. Shares of CrossFirst Bankshares, Inc. (NASDAQ:CFB) fell sharply in today's pre-market trading following second-quarter results. CrossFirst Bankshares reported quarterly earnings of 37 cents per share, according to data from Benzinga Pro. CrossFirst Bankshares shares dipped 12.3% to $13.98 in the pre-market trading session. Here are some big stocks recording losses in today's pre-market trading session. Applied Therapeutics, Inc. (NASDAQ:APLT) fell 11.8% to $5.24 in pre-market trading after gaining 7% on Monday. Owens & Minor, Inc. (NYSE:OMI) dipped 10.6% to $12.35 in pr
U.S. stock futures were mixed this morning, with the Dow futures gaining around 10 points on Friday. Shares of Wells Fargo & Company (NYSE:WFC) fell sharply in today's pre-market trading after the company posted second-quarter results. Wells Fargo earned a net income of $4.91 billion, down 1% year over year in the second quarter of 2024. The company reported a GAAP EPS of $1.33, beating the consensus of $1.29. Revenue rose 1% to $20.69 billion, according to data from Benzinga Pro. Wells Fargo shares fell 5.7% to $56.76 in the pre-market trading session. Here are some big stocks recording losses in today's pre-market trading session. NANO Nuclear Energy Inc. (NASDAQ:NNE) share
Craig-Hallum analyst Chase Knickerbocker maintains Indivior (NASDAQ:INDV) with a Buy and lowers the price target from $37 to $24.
U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.1% on Tuesday. The Dow traded down 0.05% to 39,323.7 while the NASDAQ rose 0.10% to 18,422.24. The S&P 500 also rose, gaining, 0.12% to 5,579.76. Check This Out: Nvidia To Rally Over 40%? Here Are 10 Top Analyst Forecasts For Tuesday Leading and Lagging SectorsFinancials shares jumped by 1.1% on Tuesday. In trading on Tuesday, materials shares fell by 0.6%. Top Headline Helen of Troy Limited (NASDAQ:HELE) reported soft first-quarter earnings and lowered its FY25 guidance. Equities Trading UP Soligenix, Inc. (NASDAQ:SNGX) shares shot up 379% to $9.59 after the
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). Primary and Secondary End Points of the Study were Not Met Indivior Does Not Currently Expect to Exercise AEF0117 Option SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma's announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The
BARDA purchased OPVEE, a nalmefene opioid overdose reversal nasal sprayThrough BARDA's contract with Indivior, communities will be better equipped to respond to mass poisoning emergencies and address biosecurity threats involving synthetic opioidsRICHMOND, Va., Aug. 26, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced the first order of OPVEE® (nalmefene) nasal spray from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support its ongoing national preparedness efforts and help save lives during potential synthetic opioid overdo
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). Repurchases Under Current Program now Expected to be Completed by End of JulyRICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) ("Indivior" or the "Company"), a leading addiction treatment company, today announced that its Board of Directors has approved a new share repurchase program under which the Company will commence repurchasing Indivior's ordinary shares of $0.50 each (the "Ordinary Shares") for up to a maximum consideration of $100 million (
SLOUGH, UK and RICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/mmc/p/jpgy4cd
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., July 9, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the Group's outlook for Q2 and FY 2024 financial performance, its product portfolio and litigation. Indivior is: Updating Q2 net revenue (NR) expectations and FY 2024 guidance to reflect continued adverse market dynamics impacting near-ter
Large reductions in the incidence of simulated cardiac arrest caused by potentially lethal doses of fentanyl or carfentanil were observed following a single IN dose of OPVEE compared to a single dose of IN naloxone. Across scenarios of fentanyl or carfentanil overdoses, simultaneous administration of four doses of IN naloxone (4×4 mg) was needed to reduce the incidence of simulated cardiac arrest to values approaching those obtained with a single dose of OPVEE (3mg). Modeling predictions in chronic opioid users indicate that the incidence of cardiac arrest following an intravenous (IV) fentanyl overdose (2.97 mg) decreased from 78% in the absence of intervention to 12% with OPVEE and 47% wit
Double-blind, placebo-controlled study aims to measure safety and efficacy of INDV-2000 over 3 months in participants with moderate to severe Opioid Use Disorder.INDV-2000 is an investigational non-opioid treatment that acts through the orexin pathway, shown to play a key role in the neurobiology of substance use disorder in animals.Recent animal studies have demonstrated that selective Orexin-1 receptor antagonism can reduce self-administration of opioids and synthetic opioids such as fentanyl and remifentanil.RICHMOND, Va., June 10, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced the dosing of the first subject with INDV-2000 in a Phase 2 double-blind, placebo controlled, r
RICHMOND, Va., May 23, 2024 /PRNewswire/ -- Indivior PLC ((LSE: INDV, NASDAQ:INDV), a leading addiction treatment company, announced that in anticipation of the expected primary listing of the Company's shares on Nasdaq , members of Indivior's senior leadership team will be hosting an analyst teach-in event today in New York City. The event, which will be webcast (see details below), is intended to provide an in-depth overview of Indivior's growth and value creation path. During the event, the Company will reconfirm its unchanged FY 2024 guidance as set forth below. FY 2024 Ne
SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/mm
This head-to-head pharmacodynamic study in healthy volunteers examined the ability of both OPVEE and intranasal naloxone to reverse opioid-induced respiratory depression, which is the shallow and slow breathing associated with an opioid overdoseIn this model, OPVEE 2.7mg reversed respiratory depression to 95% of pre-opioid baseline within 5 minutes; a similar reversal following a 4 mg dose of intranasal naloxone required 20 minutesRICHMOND, Va., March 11, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced respiratory depression, which is the major cause of deaths due to opioid overdose
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
6-K - INDIVIOR PLC (0001625297) (Filer)
SLOUGH, UK and RICHMOND, Va., July 25, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/mmc/p/jpgy4cd
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). RICHMOND, Va., July 9, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the Group's outlook for Q2 and FY 2024 financial performance, its product portfolio and litigation. Indivior is: Updating Q2 net revenue (NR) expectations and FY 2024 guidance to reflect continued adverse market dynamics impacting near-ter
SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/mm
SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced its financial results for the period ending December 31, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/
SLOUGH, United Kingdom, and RICHMOND, Va., July 27, 2023 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced its financial results for the period ending June 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com/mmc